Pharmacogenetics of drug hypersensitivity.
Pharmacogenetics of drug hypersensitivity.
复制标题
DOI：
10.2217/pgs.10.77
复制
发表时间：
2010-07
期刊：
影响因子：
2.1
通讯作者：
Mallal SA
中科院分区：
文献类型：
--
作者：
Phillips EJ;Mallal SA
药物超敏反应和重度皮肤药物不良反应（如Stevens-Johnson综合征和中毒性表皮坏死松解症）是通过代谢和免疫机制联合介导的严重药物不良反应的示例，传统上无法根据药物单独的药理学特征进行预测。这些综合征与特定HLA之间新关联的发现，使人们有希望通过药物遗传学筛查预测这些反应的风险，从而避免与这些类型的药物反应相关的严重发病率和死亡率。尽管如此，在将这些关联转化为可在临床环境中常规使用的药物遗传学测试方面存在一些障碍。HLA-B*5701筛查预防阿巴卡韦过敏综合征是一个例子，测试现在在发达国家广泛的常规临床使用。
Drug hypersensitivity reactions and severe cutaneous adverse drug reactions, such as Stevens–Johnson syndrome and toxic epidermal necrolysis, are examples of serious adverse drug reactions mediated through a combination of metabolic and immunological mechanisms that could traditionally not have been predicted based on the pharmacological characteristics of the drug alone. The discovery of new associations between these syndromes and specific HLA has created the promise that risk for these reactions could be predicted through pharmacogenetic screening, thereby avoiding serious morbidity and mortality associated with these types of drug reactions. Despite this, several hurdles exist in the translation of these associations into pharmacogenetic tests that could be routinely used in the clinical setting. HLA-B*5701 screening to prevent abacavir hypersensitivity syndrome is an example of a test now in widespread routine clinical use in the developed world.
登录
查看更多内容
影响因子：
11.8
作者：
DeJesus, E;Herrera, G;Scott, TR
通讯作者：
Scott, TR
影响因子：
6
作者：
Abe, R;Shimizu, T;Shimizu, H
通讯作者：
Shimizu, H
影响因子：
82.9
作者：
Chung, Wen-Hung;Hung, Shuen-Iu;Chen, Yuan-Tsong
通讯作者：
Chen, Yuan-Tsong
影响因子：
105.7
作者：
GARLEPP, MJ;DAWKINS, RL;CHRISTIANSEN, FT
通讯作者：
CHRISTIANSEN, FT
影响因子：
--
作者：
Hammond, E.;Mamotte, C.;Mallal, S.
通讯作者：
Mallal, S.